Dengue - Sample Collection Study Pakistan
A Prospective Study for the Collection of Whole Blood Samples to Support the Development and Validation of In Vitro Diagnostic Tests for Dengue
1 other identifier
observational
200
0 countries
N/A
Brief Summary
The objective of this study is to collect well-characterized serum and plasma specimens from confirmed dengue positive and dengue negative subjects to support dengue diagnostic products development.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2025
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 24, 2025
CompletedStudy Start
First participant enrolled
October 1, 2025
CompletedFirst Posted
Study publicly available on registry
October 2, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2026
CompletedOctober 2, 2025
September 1, 2025
5 months
September 24, 2025
September 24, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
sample collection only, no specific outcome needed
5 months
Study Arms (2)
dengue positives
dengue negatives
Eligibility Criteria
Subjects with symptoms suggestive of active dengue or a recent diagnosis of dengue seeking clinical care.
You may qualify if:
- Age ≥12-years-old
- Individuals suspected or confirmed for active dengue, with dengue-consistent symptoms onset up to and including 10 days before enrolment in this trial.
You may not qualify if:
- Subject has been vaccinated for dengue.
- Subject participates in an investigative drug, vaccine or medical device clinical study
- Participant is deemed unfit for the study by the Investigator
- Participant is unwilling or unable to provide informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Abbott Rapid Dxlead
- Aga Khan Universitycollaborator
- National University of Medical Sciences, Pakistancollaborator
Biospecimen
serum, plasma, no human genetic testing
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 24, 2025
First Posted
October 2, 2025
Study Start
October 1, 2025
Primary Completion
March 1, 2026
Study Completion
April 1, 2026
Last Updated
October 2, 2025
Record last verified: 2025-09